EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Colectomy and Neoplasia Outcomes of Patients With Ulcerative Colitis Receiving Golimumab: A Post‐Authorisation Safety Study Using the Spanish ENEIDA Registry

Eugeni Domènech, Joan Fortuny, David Martínez, Anita Tormos, Zhiping Huang, Deanna D Hill, Cindy Weinstein, Suzan Esslinger, Alexis A Krumme, Marijo Otero-Lobato, Daniel Mines, Javier P Gisbert und 1 weitere

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Eugeni Domènech und 12 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Colectomy, Antibodies, Monoclonal, Colonic Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA. RTI Health Solutions, an independent nonpro….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Golimumab (GLM), an anti‐tumour necrosis factor alpha (anti‐TNFα) agent, is indicated for moderate to severe ulcerative colitis (UC). This post‐authorisation safety study evaluated the risk of colectomy due to intractable disease and advanced colonic neoplasia (high‐grade dysplasia and/or colorectal cancer) under real‐world conditions of GLM use.

Methods

This bidirectional cohort study using Spanish ENEIDA registry data (2013–2022) included adults with UC who initiated GLM, other anti‐TNFα agents, or thiopurines (TPs). Crude risk analyses—and, when feasible, multivariable models—in cohort and nested case‐control designs were performed. For colectomy, we evaluated exposure to GLM only, other anti‐TNFα agents, and both (i.e., overlapping exposure). For ACN, we evaluated exposure to GLM, other anti‐TNFα agents, and TPs.

Results

Sixty‐four colectomy cases and 10 ACN cases were identified among patients exposed to GLM ( N = 474), other anti‐TNFα agents ( N = 1737), or TPs ( N = 1380). Incidence rates per 1000 person‐years and 95% confidence intervals were reported for colectomy (GLM–only [4.4, 1.2–11.2] and other anti‐TNFα agents only [12.4, 9.1–16.5]) and ACN (GLM [1.5, 0.2–5.4], other anti‐TNFα agents [1.3, 0.5–2.8], and TPs [1.0, 0.3–2.6]). In comparisons excluding overlapping exposure, GLM was not associated with an increased risk of colectomy versus other anti‐TNFα agents. GLM was also not associated with an increased risk of ACN versus either comparator. Observed events, especially for ACN, were limited for all exposures.

Conclusions

Findings do not indicate an increased risk of colectomy due to intractable disease or ACN with GLM use versus other therapies for similar disease severity in routine UC care (EUPAS15752).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeColectomyAntibodies, MonoclonalColonic NeoplasmsHumansMaleFemaleRegistriesMiddle AgedAdultSpainCase-Control StudiesTumor Necrosis Factor-alphaCohort StudiesAgedProduct Surveillance, PostmarketingYoung Adult

Stichwörter der Autor:innen

biologicscolectomycolorectal cancerepidemiologyinflammatory bowel disease (IBD)ulcerative colitis

Substanzen

golimumabAntibodies, MonoclonalTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
  • RTI Health Solutions, Barcelona, Spain.
  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • Johnson & Johnson Innovative Medicine, Zug, Switzerland.
  • Johnson & Johnson, Titusville, New Jersey, USA.

Förderung

  • This study was funded by Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA. RTI Health Solutions, an independent nonpro…

Zitieren

APA

Domènech, E., Fortuny, J., Martínez, D., Tormos, A., Huang, Z., Hill, D. D., Weinstein, C., Esslinger, S., Krumme, A. A., Otero-Lobato, M., Mines, D., Gisbert, J. P., & ENEIDA Study Group of GETECCU (2025). Colectomy and Neoplasia Outcomes of Patients With Ulcerative Colitis Receiving Golimumab: A Post‐Authorisation Safety Study Using the Spanish ENEIDA Registry. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70176

Vancouver

Domènech E, Fortuny J, Martínez D, Tormos A, Huang Z, Hill DD, et al. Colectomy and Neoplasia Outcomes of Patients With Ulcerative Colitis Receiving Golimumab: A Post‐Authorisation Safety Study Using the Spanish ENEIDA Registry. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70176

BibTeX
@article{Domnech2025,
  author = {Domènech, Eugeni and Fortuny, Joan and Martínez, David and Tormos, Anita and Huang, Zhiping and Hill, Deanna D and Weinstein, Cindy and Esslinger, Suzan and Krumme, Alexis A and Otero-Lobato, Marijo and Mines, Daniel and Gisbert, Javier P and ENEIDA Study Group of GETECCU, ENEIDA Study Group of GETECCU},
  title = {Colectomy and Neoplasia Outcomes of Patients With Ulcerative Colitis Receiving Golimumab: A Post‐Authorisation Safety Study Using the Spanish ENEIDA Registry},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70176}
}
Kostenlos starten →